Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is the moderator of the discussion presented in this article. The experts comment on two clinical trials of selective estrogen receptor degraders (SERDs) for treatment of metastatic breast cancer. Results of both trials were presented at the San Antonio Breast Cancer Symposium.
